LitAlert ~~ GeneLit.com

    • Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
    • Kindler HL, Yoo HK, Hettle R, Cui KY, Joo S, Locker GY, Golan T.
    • Cancer. 2023 Feb 22. doi: 10.1002/cncr.34610. Epub ahead of print.

    • PARP Inhibitors Will "Remain Relevant" for mCRPC.
    • [No author given]
    • Cancer Discov. 2023 Feb 22:OF1. doi: 10.1158/2159-8290.CD-NB2023-0013. Epub ahead of print.
    • Research news

    • Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2.
    • Bhardwaj P, Iyengar NM, Zahid H, Carter KM, Byun DJ, Choi MH, Sun Q, Savenkov O, Louka C, Liu C, Piloco P, Acosta M, Bareja R, Elemento O, Foronda M, Dow LE, Oshchepkova S, Giri DD, Pollak M, Zhou XK, Hopkins BD, Laughney AM, Frey MK, Ellenson LH, Morrow M, Spector JA, Cantley LC, Brown KA.
    • Sci Transl Med. 2023 Feb 22;15(684):eade1857. doi: 10.1126/scitranslmed.ade1857. Epub 2023 Feb 22.

    • Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: A retrospective analysis at a single facility.
    • Kawamura M, Shirota H, Niihori T, Komine K, Takahashi M, Takahashi S, Miyauchi E, Niizuma H, Kikuchi A, Tada H, Shimada M, Kawamorita N, Kanamori M, Sugiyama I, Tsubata M, Ichikawa H, Yasuda J, Furukawa T, Aoki Y, Ishioka C.
    • J Hum Genet. 2023 Feb 20. doi: 10.1038/s10038-023-01133-5. Epub ahead of print.

    • Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety.
    • Lee M, Je IG, Kim JE, Yoo Y, Lim JH, Jang E, Lee Y, Song DK, Moon AN, Kim JA, Jeong J, Park JT, Lee JW, Yang JH, Hong CH, Park SY, Park YW, Baek NS, Lee S, Ha KS, Choi S, Lee WS.
    • Mol Cancer Ther. 2023 Feb 20:OF1-OF10. doi: 10.1158/1535-7163.MCT-22-0068. Epub ahead of print.

    • Psychosocial factors impacting barriers and motivators to cancer genetic testing.
    • Hanson EN, Delacroix E, Austin S, Carr G, Kidwell KM, Bacon E, Gerido LH, Griggs JJ, Stoffel EM, Resnicow K.
    • Cancer Med. 2023 Feb 19. doi: 10.1002/cam4.5709. Epub ahead of print.

    • Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma.
    • Pitiyarachchi O, Lee YC, Sim HW, Srirangan S, Mapagu C, Kirk J, Harnett PR, Balleine RL, Bowtell DDL, Samimi G, Brand AH, Marsh DJ, Beale P, Anderson L, Bouantoun N, Provan P; INOVATe Investigators; Ramus SJ, DeFazio A, Friedlander M.

    • A case of unresectable intrahepatic cholangiocarcinoma with a germline BRCA1 mutation.
    • Yamashita Y, Ishii Y, Serikawa M, Okamoto W, Tsuboi T, Tatsukawa Y, Nakamura S, Hirano T, Ikemoto J, Oka S.
    • Clin J Gastroenterol. 2023 Feb 17. doi: 10.1007/s12328-023-01772-3. Epub ahead of print.
    • Case report

    • Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
    • Colomban O, Swisher EM, Kristeleit R, McNeish I, Shapira-Frommer R, Goble S, Lin KK, Maloney L, Freyer G, You B.
    • EBioMedicine. 2023 Feb 16;89:104477. doi: 10.1016/j.ebiom.2023.104477. Epub ahead of print.

    • Clinicopathological and imaging features of ductal carcinoma in situ in BRCA1/2 mutation carriers.
    • Seki A, Tsunoda H, Takei J, Suzuki M, Kanomata N, Yamauchi H.
    • Breast Dis. 2023;42(1):5-15. doi: 10.3233/BD-220006.